Physician profile
James Orlando
NPI 1285604207
$19,661.38
in general payments reported to CMS, 2019-2025
42 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,553 · 2020: $2,151 · 2021: $4,847 · 2022: $2,893 · 2023: $2,951 · 2024: $2,382 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,217.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,867.48 | 2019-2025 | Mitraclip, Dragonfly Opstar, Jot Dx |
| Astrazeneca Pharmaceuticals LP | $2,107.38 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Janssen Pharmaceuticals, INC | $1,794.84 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,749.81 | 2019-2025 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $845.90 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $837.89 | 2020-2024 | Nexletol, Nexlizet |
| Medtronic, INC. | $724.29 | 2022-2025 | Symplicity G3, Ffrangio, Onyx Frontier |
| Amgen INC. | $708.35 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $691.90 | 2021-2025 | |
| Pfizer INC. | $560.60 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $544.59 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $514.70 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Cvrx, INC. | $473.17 | 2021-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $446.43 | 2019-2024 | Camzyos, Eliquis |
| Kowa Pharmaceuticals America, INC. | $410.15 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $355.89 | 2019-2022 | |
| Boston Scientific Corporation | $341.49 | 2019-2025 | Watchman Flx, Watchman, Avvigo Guidance System |
| Merck Sharp & Dohme LLC | $241.82 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $232.36 | 2019-2023 | |
| Tactile Systems Technology INC | $137.00 | 2020-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Actelion Pharmaceuticals US, INC. | $136.53 | 2023-2025 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $131.55 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $116.56 | 2021 | |
| W. L. Gore & Associates, INC. | $103.84 | 2020-2023 | Gore Cardioform Septal Occluder |
| Kiniksa Pharmaceuticals, LTD. | $103.55 | 2021-2023 | Arcalyst |
| Gilead Sciences, INC. | $64.93 | 2019 | |
| Kestra Medical Technology Services, INC. | $46.80 | 2024 | Assure Wcd |
| Bridgebio Pharma, INC. | $43.40 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $43.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.68 | 2025 | Onpattro |
| Medtronic Vascular, INC. | $27.26 | 2019 | |
| Imperative Care, INC | $25.96 | 2025 | Symphony Catheter |
| Atricure, INC. | $25.17 | 2024 | |
| Globus Medical, INC. | $24.98 | 2025 | Senza |
| Medicure Pharma INC. | $24.65 | 2021 | |
| Bardy Diagnostics, INC. | $23.04 | 2019 | |
| Scpharmaceuticals INC. | $17.73 | 2024 | |
| Potrero Medical, INC. | $17.12 | 2023 | |
| Daiichi Sankyo INC. | $16.11 | 2023 | Injectafer |
| Angiodynamics, INC. | $15.71 | 2024 | Auryon Laser System 100-120 Vac |
| Altathera Pharmaceuticals LLC | $15.52 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.90 | 2024 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Orlando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.